A team led by cancer expert Guido Wollmann from the Medical University of Innsbruck has succeeded in shedding light on the advantages of a combined tumor vaccination. The results were published on Tuesday in a renowned specialist journal. A clinical test phase of the mixed vaccination should start soon, Wollmann was quoted in a broadcast. The substances are in “advanced preclinical or clinical development”.
Advantages of heterologous vaccines
The joint study with the Med-Uni Vienna and biotech partners from the pharmaceutical industry ran for four years. Experts tested the effectiveness of the combination vaccination in four different tumor models, each of which represented different tumor types in humans. It turned out that the best combination is an initial vaccination (primer) with the KISIMA protein platform and a boost (booster) with a virus vector vaccination.
“Our study has laid scientific foundations that show the advantages of the heterologous vaccine combination and that with two platforms that are already in advanced preclinical and clinical development,” said Wollmann, who opposes the Christian Doppler research laboratory for viral immunotherapy Krebs at the Institute for Virology of the Medical University of Innsbruck heads the current state of research.
Essentially three positive effects could be achieved through the mixed vaccination, it said. Initially, the researchers recorded significantly more potent T cells. These would have released significantly more cytokines and other substances to kill tumors and developed into longer-lived cells with memory functions. In addition, the injection of the virus vector vaccine causes an infection inside the tumor. The immune system perceives the virus as a pathogen, explained Wollmann: “Tumors tend to have an immune-inhibiting environment. The virus infection opens the gates to the tumor”. Thirdly, the model of a tumor that has not responded to immunotherapy from the outset has shown that the effects of mixed vaccination can be intensified by the additional administration of a special immunotherapy.